657-P: Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 657-P
Author(s):  
JONG SUK LEE ◽  
JUNG KUK KIM ◽  
SEON MYEONG LEE ◽  
JAEHYUK CHOI ◽  
EUNJIN PARK ◽  
...  
Keyword(s):  
Animal Models ◽  
Metabolic Disorders ◽  
Potential Effect ◽  
Long Acting

1925-P: Beneficial Effects of a Novel Long-Acting Glucagon Analog, HM15136, on Obesity and Obesity-Related Metabolic Disorders in Animal Models

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1925-P
Author(s):  
JONG SUK LEE ◽  
SEON MYEONG LEE ◽  
JAEHYUK CHOI ◽  
EUNJIN PARK ◽  
JONGSOO LEE ◽  
...  
Keyword(s):  
Animal Models ◽  
Metabolic Disorders ◽  
Beneficial Effects ◽  
Long Acting

109-LB: Potent Weight Loss Mechanism by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 109-LB
Author(s):  
JONG SUK LEE ◽  
JUNG KUK KIM ◽  
JINYOUNG KIM ◽  
EUNJIN PARK ◽  
SANG HYUN LEE ◽  
...  
Keyword(s):  
Weight Loss ◽  
Animal Models ◽  
Loss Mechanism ◽  
Long Acting

scholarly journals Maternal Obesity and Developmental Programming of Metabolic Disorders in Offspring: Evidence from Animal Models

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
M. Li ◽  
D. M. Sloboda ◽  
M. H. Vickers
Keyword(s):  
Animal Models ◽  
Early Life ◽  
Metabolic Disorders ◽  
Maternal Obesity ◽  
Maternal Weight ◽  
Critical Window ◽  
Obesity Epidemic ◽  
Obesity And Overweight ◽  
Increased Risk ◽  
Maternal Overnutrition

The incidence of obesity and overweight has reached epidemic proportions in the developed world as well as in those countries transitioning to first world economies, and this represents a major global health problem. Concern is rising over the rapid increases in childhood obesity and metabolic disease that will translate into later adult obesity. Although an obesogenic nutritional environment and increasingly sedentary lifestyle contribute to our risk of developing obesity, a growing body of evidence links early life nutritional adversity to the development of long-term metabolic disorders. In particular, the increasing prevalence of maternal obesity and excess maternal weight gain has been associated with a heightened risk of obesity development in offspring in addition to an increased risk of pregnancy-related complications. The mechanisms that link maternal obesity to obesity in offspring and the level of gene-environment interactions are not well understood, but the early life environment may represent a critical window for which intervention strategies could be developed to curb the current obesity epidemic. This paper will discuss the various animal models of maternal overnutrition and their importance in our understanding of the mechanisms underlying altered obesity risk in offspring.

scholarly journals Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

2020 ◽  
Vol 11 ◽  
Author(s):  
Manjula Gunawardana ◽  
Mariana Remedios-Chan ◽  
Debbie Sanchez ◽  
Simon Webster ◽  
Patricia Galvan ◽  
...  
Keyword(s):  
Animal Models ◽  
Active Agent ◽  
The Body ◽  
Dermal Tissue ◽  
Metabolite Concentrations ◽  
Tenofovir Alafenamide ◽  
Long Acting ◽  
Exposure Prophylaxis ◽  
Hiv 1 ◽  
Subdermal Implant

New HIV-1 infection rates far outpace the targets set by global health organizations, despite important progress in curbing the progression of the epidemic. Long-acting (LA) formulations delivering antiretroviral (ARV) agents for HIV-1 pre-exposure prophylaxis (PrEP) hold significant promise, potentially facilitating adherence due to reduced dosing frequency compared to oral regimens. We have developed a subdermal implant delivering the potent ARV drug tenofovir alafenamide that could provide protection from HIV-1 infection for 6 months, or longer. Implants from the same lot were investigated in mice and sheep for local safety and pharmacokinetics (PKs). Ours is the first report using these animal models to evaluate subdermal implants for HIV-1 PrEP. The devices appeared safe, and the plasma PKs as well as the drug and metabolite concentrations in dermal tissue adjacent to the implants were studied and contrasted in two models spanning the extremes of the body weight spectrum. Drug and drug metabolite concentrations in dermal tissue are key in assessing local exposure and any toxicity related to the active agent. Based on our analysis, both animal models were shown to hold significant promise in LA product development.

scholarly journals The Potential Effect of Aqueous Extract of Detarium microcarpum Bark on Certain Metabolic Disorders Associated with an Atherogenic Diet in Rats

2020 ◽  
Vol 9 (5) ◽  
pp. 102
Author(s):  
Youovop Fotso Janvier ◽  
Mbaississem Walendom Dieudonné ◽  
Ngondi Judith Laure ◽  
Julius Enyong Oben
Keyword(s):  
Cardiac Function ◽  
Aqueous Extract ◽  
Metabolic Disorders ◽  
Risk Index ◽  
Hepatic Function ◽  
Potential Effect ◽  
Atherogenic Diet ◽  
Bark Extract ◽  
Vascular Protection ◽  
Detarium Microcarpum

Atherosclerosis is the leading cause of the cardiovascular disease (CVD). This study aimed to evaluate the effect of the aqueous extract of Detarium microcarpum on metabolic disorders in rats fed with an atherogenic diet. The extract at two doses (200 mg/kg and 400 mg/kg) was co-administered in rats with an atherogenic diet. After 28 days, rats were sacrificed, blood collected in ethylene diamine tetraacetic acid (EDTA) tubes for plasma preparation, and the heart used for homogenate preparation. These plasma and heart homogenates were used to assess lipid profile, cardiac function (NO, ASAT), and hepatic function (ALAT, ASAT, and totals proteins). The results obtained showed that treatment (200 mg/kg and 400 mg/kg extract) led to a significant decrease in TG, VLDL-c, LDL-c, HDL-c, and non-HDL-c compared to untreated rats (positive control) (p < 0.001). Similarly, the cardiovascular risk index (IR, CRR, AC and AIP), were significantly low in the treated groups compared to untreated groups (p < 0.001). Meanwhile, the CPI was higher in threated groups (p < 0.001). The percentage of vascular protection in rats receiving the extract was higher compared to rats treated with atorvastatin. The evaluation of cardiac function showed high levels of NO and ASAT in the heart of rats treated with the extract (p < 0.05). The plasma activity of ASAT and ALAT was low in the groups treated with the extract (p < 0.05). A low plasma level of total protein was also observed in the same groups (p < 0.001). Therefore, the aqueous bark extract of D. microcarpum administered orally showed anti-atherogenic, cardioprotective, and hepatoprotective potential.

The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality

2016 ◽  
Vol 26 (4) ◽  
pp. 446-458
Author(s):  
Catherine B. Johannes ◽  
Lisa J. McQuay ◽  
Kirk D. Midkiff ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
Keyword(s):  
Corticosteroid Therapy ◽  
Potential Effect ◽  
Inhaled Corticosteroid ◽  
Beta Agonists ◽  
Long Acting ◽  
Asthma Mortality
Sign in / Sign up

Export Citation Format

Share Document